Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation

Bone Marrow Transplantation

Volumn 25, Issue 11, 2000, Pages 1121-1127

  Simonsson, B ^a   Totterman T ^b   Hokland, P ^b   Lauria, F ^b   Carella, A M ^b   Fernandez, M N ^b   Rozman, C ^b   Ferrant, A ^b   De Witte, T ^b   Zander, A R ^b   Meier, K ^b   Hansson, F ^b   Nilsson, B I ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

ABMT; AML; Linomide; Roquinimex

Indexed keywords

ROQUINIMEX;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW PURGING; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; VOMITING;

EID: 0342264631     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702411     Document Type: Article

References (45)

1. Volm MD, Tallman MS. Developments in the treatment of acute leukemia in adults. Curr Opin Oncol 1995; 7: 28-35.
2. Greer JP, Kinney MC. Acute nonlymphocytic leukemia. In: Lee RG, Bithell TC, Foerster J et al (eds). Wintrobe's Clinical Hematology. Lee and Febiger: Philadelphia, 1993, pp 1920-1945.
3. Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Engl J Med 1995; 332: 217-223.
4. Körbling M, Hunstein W, Fliedner TM et al. Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia. Blood 1989; 74: 1898-1904.
5. Reiffers J, Gaspard MH, Maraninchi D et al. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukemia in first remission: a prospective controlled trial. Br J Haematol 1989; 72: 57-63.
6. Cassileth PA, Anderson J, Lazarus HM et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol 1993; 11: 314-319.
7. Sierra J, Grañena A, García J et al. Autologous bone marrow transplantation for acute leukemia: results and prognostic factors in 90 consecutive patients. Bone Marrow Transplant 1993; 12: 517-523.
8. Weiden PL, Keith M, Sullivan KM et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. New Engl J Med 1981; 304: 1529-1533.
9. Sullivan KM, Fefer A, Witherspoon R. Graft-versus-leukemia in man: relationship with acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation. In: Truitt RL, Gale RP, Bortin MM (eds). Cellular Immunotherapy of Cancer. Alan R Liss: New York, 1987, pp 391-399.
10. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
11. Löwenberg B, Wagemarker G, van Bekkum DW et al. Graft-versus-host disease following transplantation of 'one log' vs 'two log' T lymphocyte-depleted bone marrow from HLA-identical donors. Bone Marrow Transplant 1986; 1: 133-140.
12. Sosman JA, Oettel KR, Smith SD et al. Specific recognition of human leukemia cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells. Blood 1990; 75: 2005-2016.
13. Faber LM, van Luxemburg-Heijs SAP, Willemze R, Falkenburg JHF. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 1992; 176: 1283-1289.
14. Dawson MM, Johnston D, Taylor GM, Moore M. Lymphokine activated killing of fresh human leukaemias. Leukemia Res 1986; 10: 683-688.
15. Oshimi K, Oshimi Y, Akutsu M et al. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 1986; 68: 938-948.
16. Lauria F, Raspadori D, Rondelli D et al. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival. Leukemia 1994; 8: 724-728.
17. Hoffman T, Theobald M, Bunjes D et al. Frequency of bone marrow T cells responding to HLA-identical non-leukemic and leukemic stimulator cells. Bone Marrow Transplant 1993; 12: 1-8.
18. Lotzová E, Savary CA, Herberman RB. Induction of NK cell activity against fresh human leukemia in culture with interleukin-2. J Immunol 1987; 138: 2718-2727.
19. Reittie JE, Gottlieb D, Heslop HE et al. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 1989; 73: 1351-1358.
20. Archimbaud E, Bailly M, Doré J-F. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukemia in complete remission and its clinical relevance. Br J Haematol 1991; 77: 328-334.
21. Pizzolo G, Trentin L, Vinante F et al. Natural killer cell function in lymphoid cell populations in acute non-lymphoblastic leukemia in complete remission. Br J Cancer 1988; 58: 268-272.
22. Adler A, Albo V, Blatt J et al. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission. Blood 1989; 74: 1690-1697.
23. Nasrallah AG, Miale TD. Decreased natural killer cell activity in children with untreated acute leukemia. Cancer Res 1983; 43: 5580-5585.
24. Sørskaar D, Førre Ø, Albrechtsen D, Stavem P. Decreased natural killer cell activity versus normal natural killer cell markers in mononuclear cells from patients with smouldering leukemia. Scand Haematol 1986; 37: 154-161.
25. Guillou PJ, Sedman PC, Ramsden CW. Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro. Cancer Immunol Immunother 1989; 28: 43-53.
26. Melzer MS, Nacy CA. Delayed-type hypersensitivity and the induction of activated, cytotoxic macrophages. In: Paul WE (ed). Fundamental Immunology. Raven Press: New York, 1989; pp 765-777.
27. Nathan CF, Cohn ZA. Cellular components of inflammation: monocytes and macrophages. In: Kelly WN, Harris ED Jr, Ruddy S, Sledge CB (eds). Textbook of Rheumatology. WB Saunders Co: Philadelphia, 1985, pp 144-169.
28. Fidler IJ, Schroit AJ. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim Biophys Acta 1988; 948: 151-173.
29. Drysdale BE, Agarwal S, Shin HS. Macrophage-mediated tumoricidal activity: Mechanisms of activation and cytotoxicity. Prog Allergy 1988; 40: 111-161.
30. Hamilton TA, Adams DO. Mechanisms of macrophage-mediated tumor injury. In: Den Otter W, Ruitenberg EJ (eds). Tumor Immunology: Mechanisms, Diagnosis, Therapy. Elsevier: Amsterdam. 1987, pp 89-107.
31. Kalland T, Aim G, Stålhandske T. Augmentations of mouse natural killer cell activity by LS 2626, a new immunomodulator. J Immunol 1985; 134: 3956-3961.
32. Kalland T. Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J Immunol 1990; 144: 4472-4476.
33. Larsson E-L, Joki A, Stålhandske T. Mechanism of action of the immunomodulator LS 2616 on T-cell responses. Int J Immunopharmacol 1987; 9: 425-431.
34. Stålhandske T, Kalland T. Effects of the novel immunomodulator LS 2616 on the delayed type hypersensitivity reaction to Bordetella pertussis in the rat. Immunopharmacol 1986; 11: 87-92.
35. Sabzevari H, Koo GC, Szalay J. The effect of Linomide on growth and metastasis of mammary adenocarcinoma in the Fischer 344 rat. J Exp Clin Cancer Res 1994; 13: 21-30.
36. Nived O, Sturfelt G, Nilsson B et al. Clinical pilot study of Roquinimex ((Linomide) in patients with autoimmune disease. InI J Immunother 1994; 10: 49-59.
37. Bergh JCS, Tötterman TH, Termander BC et al. A clinical pilot study ot Roquinimex (Linomide) in cancer patients with special forms on immunological effects. Cancer Invest 1997; 15: 204-211.
38. Hokland M, Jørgensen H, Holm MS et al. Natural effector cells in patients with acute myeloid leukemia treated with the immunodulator Linomide after autologous bone marrow transplantation. Eur J Haematol 1999; 63: 251-258.
39. Bengtsson M, Simonsson B, Carlsson K et al. Stimulation of NK cell, T cell and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. Transplantation 1992; 53: 882-888.
40. Nilsson BI, Simonsson B, Bengtsson M et al. Immunotherapy of AML after ABMT - scientific rationale and early experiences with Linomide. In: Dicke KA. Keating A (eds). Autologous Bone Marrow Transplantation - Proceedings of the Sixth International Symposium. Cancer Treatment Research Education Fund: Arlington, Texas, 1993, pp 38-44.
41. Fefer A, Benyunes M, Higuchi C et al. Interleukin-2 ± lymphocytes as consolidate immunotherapy after autologous bone marrow transplantation for hematologic malignancies. Acta Haematol 1993; 89 (Suppl. 1): 2-7.
42. MacDonald D, Jiang Y, Gordon AA et al. Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study. Leukemia Res 1990; 14: 967-973.
43. Brune M, Hansson M, Mellqvist U-H et al. NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur J Haematol 1996; 57: 312-319.
44. Mielcarek M, Martin PJ, Torok-Storb B. Suppresion of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 1997; 89: 1629-1634.
45. Hansson M, Asea A, Ericsson U et al. Induction of apoptosis in natural killer cells by monocyte-derived reactive oxygen metabolites. J Immunol 1996; 156: 42-47.